

# Global Gastrointestinal Market Growth (Status and Outlook) 2026-2032

<https://marketpublishers.com/r/G5D2AAEDFA67EN.html>

Date: October 2026

Pages: 158

Price: US\$ 3,660.00 (Single User License)

ID: G5D2AAEDFA67EN

## Abstracts

The global Gastrointestinal market size is predicted to grow from US\$ 81830 million in 2025 to US\$ 119565 million in 2032; it is expected to grow at a CAGR of 5.4% from 2026 to 2032.

Gastrointestinal in this study refers to medicines used for the prevention, treatment and long-term management of diseases affecting the stomach, intestine, liver, gallbladder, pancreas and related digestive functions. The research scope covers established therapeutic categories including antacids and acid-control therapies, gastrointestinal prokinetics, antidiarrheals, laxatives, gastric mucosal protectants, digestive enzyme preparations and hepatobiliary drugs, while also reflecting the increasing role of targeted and advanced therapies in chronic gastrointestinal diseases. These products act through mechanisms such as gastric-acid suppression, mucosal protection, gastrointestinal motility regulation, stool-frequency and consistency control, digestive-enzyme supplementation, modulation of intestinal function and hepatobiliary regulation. Major clinical demand arises from gastritis, peptic ulcer, gastroesophageal reflux disease, dyspepsia, *Helicobacter pylori* infection, constipation, diarrhea, irritable bowel syndrome, inflammatory bowel disease and selected hepatobiliary disorders. The Gastrointestinal market therefore combines large-volume mature therapies with higher-value innovative medicines, creating a diversified pharmaceutical market characterized by substantial differences in treatment duration, clinical complexity, pricing and commercialization models.

## Key Findings

Mature therapies maintain scale but face sustained pricing pressure

P-CAB adoption is upgrading the acid-control treatment segment

IBD value growth is shifting toward targeted advanced therapies

China offers substantial structural upgrade opportunities in chronic gastrointestinal care

## Market Trends

The Gastrointestinal market is moving from a predominantly symptom-control model toward a more differentiated structure combining conventional high-volume medicines with mechanism-based and disease-modifying therapies. Mature categories such as conventional acid-control drugs, antidiarrheals, laxatives, prokinetics and mucosal protectants remain important because of their broad patient base and recurring demand, but their commercial value is increasingly constrained by generic competition and pricing pressure. At the innovation end, P-CAB therapies are expanding treatment options in acid-related diseases, while chronic inflammatory gastrointestinal diseases are increasingly treated with biologics and targeted small molecules, including IL-23 and JAK pathway therapies. Regulatory expansion of P-CAB indications across erosive and non-erosive GERD and continued development of targeted therapies in Crohn's disease and ulcerative colitis reinforce this structural transition. The long-term direction of the market is therefore not simply greater medicine consumption, but an increase in treatment precision, durability of disease control, convenient administration and lifecycle management.

## Market Dynamics

### Drivers

Demand for Gastrointestinal medicines is supported by the unusually broad patient base across acute, recurrent and chronic digestive diseases. Acid-related disorders, functional gastrointestinal conditions, constipation and diarrhea generate large recurring treatment volumes, while chronic conditions such as inflammatory bowel disease require longer treatment duration and continuous disease management. Greater diagnosis and treatment standardization are also increasing the proportion of patients receiving sustained pharmaceutical intervention rather than episodic symptom relief. At the same time, new mechanisms and improved formulations are extending treatment options in areas where conventional medicines provide incomplete response. The continued commercial importance of gastroenterology portfolios at major pharmaceutical companies, together with ongoing expansion of therapies for ulcerative

colitis, Crohn's disease and other chronic gastrointestinal conditions, confirms that long-term treatment demand has become an increasingly important value driver for the Gastrointestinal market.

## **Restraints**

The principal restraint on the Gastrointestinal market is the widening economic gap between mature and innovative therapies. Many traditional gastrointestinal medicines have well-established mechanisms, numerous generic alternatives and relatively low barriers to therapeutic substitution, resulting in sustained price competition and limited room for premium pricing. In innovative segments, development costs, clinical-trial requirements and regulatory standards are substantially higher, while reimbursement decisions increasingly depend on demonstrated clinical differentiation and long-term outcomes. Gastrointestinal diseases are also highly heterogeneous, and treatment response may vary according to disease severity, phenotype, previous therapies and patient characteristics. As a result, a clinically successful product does not automatically translate into rapid commercial penetration. Safety monitoring and long-term risk-benefit assessment are particularly important for systemic advanced therapies, increasing the evidence burden required to support broader treatment adoption.

## **Opportunities**

The most attractive opportunities are concentrated in structural substitution rather than simple expansion of established drug volumes. In acid-related disease, P-CAB technology creates opportunities to upgrade treatment pathways in GERD and H. pylori-related therapy and to capture value from patients with persistent or recurrent symptoms. In chronic gastrointestinal disease, biologics and targeted oral therapies provide additional opportunities through earlier-line use, additional indications, optimized administration and improved long-term disease control. China represents another important structural opportunity as standardized diagnosis, H. pylori management, access to targeted IBD medicines and biosimilar development gradually reshape the treatment mix. At the same time, functional disorders such as irritable bowel syndrome and chronic constipation continue to present unmet needs because treatment outcomes remain variable and patients frequently cycle through different therapeutic approaches. These areas provide room for differentiated mechanisms, improved adherence and more precise patient selection.

## **Challenges**

The Gastrointestinal market faces a dual commercialization challenge. Mature

medicines must compete primarily through manufacturing efficiency, price, product quality and broad distribution, while innovative medicines require stronger clinical differentiation, physician adoption, reimbursement access and lifecycle management. This creates very different success factors within the same overall market. For innovative therapies, increasingly crowded treatment pathways can raise the threshold for demonstrating incremental clinical value, particularly as multiple biologic and targeted mechanisms become available for the same chronic gastrointestinal indication. Companies must also balance expansion of treatment duration and indications against long-term safety requirements and affordability constraints. In emerging markets, improving access may increase patient penetration but can simultaneously intensify price competition. Consequently, sustainable growth depends increasingly on the ability to demonstrate clinically meaningful differentiation while maintaining economically acceptable treatment costs.

## Industry Chain Analysis

The Gastrointestinal industry chain begins with pharmaceutical APIs, intermediates, excipients, formulation materials and, for biologic products, cell-culture materials and specialized bioprocessing inputs. Midstream value creation includes drug discovery, formulation development, clinical development, regulatory registration, manufacturing, quality control and lifecycle management. Manufacturing economics differ substantially across product categories. Mature oral gastrointestinal drugs generally have standardized production processes and relatively high competitive exposure to API costs, manufacturing efficiency and scale, whereas innovative biologics and targeted therapies place greater value on intellectual property, clinical evidence, complex manufacturing capability and regulatory expertise. Downstream commercialization is conducted mainly through hospitals, retail pharmacies and specialized pharmaceutical distribution channels, with the relative importance of each channel varying by disease severity and treatment complexity. Conventional symptom-relief products depend heavily on broad distribution and availability, while advanced therapies rely more strongly on specialist physicians, diagnosis pathways, reimbursement access and patient-management capabilities. Consequently, the value pool is gradually shifting from manufacturing-centered mature products toward R&D, clinical evidence and differentiated therapeutic outcomes.

## Segment Insights

Within the established Gastrointestinal classification, antacids and acid-control medicines, gastrointestinal prokinetics, antidiarrheals, laxatives, gastric mucosal

protectants, digestive enzymes and hepatobiliary drugs continue to form the broad foundation of market demand. These categories benefit from large patient populations and frequent use, but many are mature and therefore face stronger generic competition and price sensitivity. Their strategic importance lies more in stable volume, brand recognition and channel coverage than in rapid value expansion. In contrast, the higher-value portion of the market is increasingly associated with technological and therapeutic upgrades. P-CAB products represent an important innovation within acid-control treatment, while targeted therapies are reshaping chronic inflammatory gastrointestinal disease management. The resulting market structure is increasingly polarized: mature products provide demand stability and commercial scale, whereas innovative therapies contribute disproportionately to incremental value creation. This divergence is expected to remain a defining characteristic of the Gastrointestinal market.

## **Downstream Market Opportunities**

Downstream demand spans both common digestive symptoms and diseases requiring prolonged specialist management. Gastritis, peptic ulcer, dyspepsia, GERD, constipation and diarrhea provide a broad base of recurring pharmaceutical demand, while *H. pylori* infection creates opportunities linked to standardized eradication therapy and acid-control optimization. Chronic diseases such as inflammatory bowel disease have a different commercial profile because treatment may extend for years and therapeutic switching, maintenance treatment and monitoring become important components of patient management. Functional disorders such as irritable bowel syndrome and chronic constipation also remain commercially relevant because symptom recurrence and heterogeneous treatment response can lead to repeated use of multiple drug classes. Downstream opportunities are therefore shifting from simply increasing patient numbers toward improving diagnosis, extending effective treatment duration, increasing adherence and moving appropriate patients toward more differentiated therapies.

## **Regional Insights**

The Gastrointestinal market displays a clear regional difference between pharmaceutical value and treatment volume. North America and Western Europe represent high-value markets for innovative gastrointestinal therapies because specialist treatment pathways, advanced biologics and targeted medicines have comparatively strong penetration, while mature gastrointestinal medicines remain highly competitive. Continued investment by major pharmaceutical companies in Crohn's disease and ulcerative colitis illustrates the commercial importance of advanced

gastrointestinal treatment in developed markets. Asia represents a structurally important market because of its large patient population and the coexistence of substantial conventional-drug demand with increasing adoption of innovative therapies. China is particularly relevant to future market restructuring: opportunities are increasingly linked to treatment standardization, improved diagnosis of chronic gastrointestinal disease, wider access to targeted medicines, localization and biosimilar competition. Regional growth potential therefore depends not only on patient numbers, but also on the speed at which treatment pathways shift from basic symptom management toward standardized and higher-value chronic disease management.

## Report Scope

LPI (LP Information)' newest research report, the “Gastrointestinal Industry Forecast” looks at past sales and reviews total world Gastrointestinal sales in 2025, providing a comprehensive analysis by region and market sector of projected Gastrointestinal sales for 2026 through 2032. With Gastrointestinal sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Gastrointestinal industry.

This Insight Report provides a comprehensive analysis of the global Gastrointestinal landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Gastrointestinal portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Gastrointestinal market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Gastrointestinal and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Gastrointestinal.

This report presents a comprehensive overview, market shares, and growth opportunities of Gastrointestinal market by product type, application, key players and key regions and countries.

## Market Segmentation

## **Segmentation by Type:**

Acid-Related Disorder Drugs

Inflammatory Bowel Disease Drugs

Irritable Bowel Syndrome Drugs

Constipation Drugs

Diarrhea Drugs

Gastrointestinal Motility Disorder Drugs

Other Gastrointestinal Drugs

## **Segmentation by Primary Dosage Form:**

Oral Solid Preparations

Oral Liquid and Suspension Preparations

Injectable Preparations

Rectal Preparations

Other Preparations

## **Segmentation by Drug Molecule:**

Small Molecule Drugs

Biologic Drugs

## **Segmentation by Application:**

Hospitals

Gastroenterology Clinics

Retail Pharmacies

Online Pharmacies

**This report also splits the market by region:**

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

AstraZeneca

Sanofi

Bayer

Pfizer

GlaxoSmithKline

Teva

Ferring Pharmaceuticals

Perrigo

Boehringer Ingelheim

Purdue Pharma

Dr. Falk Pharma GmbH

Abbott

Jiangzhong

Xian-Janssen

Takeda Pharmaceutical

AbbVie

Eli Lilly and Company

Johnson & Johnson

Bristol Myers Squibb

Bausch Health

Livzon Pharmaceutical

Shandong Luoxin Pharmaceutical

Gilead Sciences

Zhengdatianqing

Zydus Lifesciences

## Contents

### 1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

### 2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
  - 2.1.1 Global Gastrointestinal Market Size (2021-2032)
  - 2.1.2 Gastrointestinal Market Size CAGR by Region (2021 VS 2025 VS 2032)
  - 2.1.3 World Current & Future Analysis for Gastrointestinal by Country/Region (2021, 2025 & 2032)
- 2.2 Gastrointestinal Segment by Type
  - 2.2.1 Acid-Related Disorder Drugs
  - 2.2.2 Inflammatory Bowel Disease Drugs
  - 2.2.3 Irritable Bowel Syndrome Drugs
  - 2.2.4 Constipation Drugs
  - 2.2.5 Diarrhea Drugs
  - 2.2.6 Gastrointestinal Motility Disorder Drugs
  - 2.2.7 Other Gastrointestinal Drugs
  - 2.2.8 Gastrointestinal Market Size by Type
    - 2.2.8.1 Gastrointestinal Market Size CAGR by Type (2021 VS 2025 VS 2032)
    - 2.2.8.2 Global Gastrointestinal Market Size Market Share by Type (2021-2026)
- 2.3 Gastrointestinal Segment by Primary Dosage Form
  - 2.3.1 Oral Solid Preparations
  - 2.3.2 Oral Liquid and Suspension Preparations
  - 2.3.3 Injectable Preparations
  - 2.3.4 Rectal Preparations
  - 2.3.5 Other Preparations
  - 2.3.6 Gastrointestinal Market Size by Primary Dosage Form
    - 2.3.6.1 Gastrointestinal Market Size CAGR by Primary Dosage Form (2021 VS 2025)

VS 2032)

2.3.6.2 Global Gastrointestinal Market Size Market Share by Primary Dosage Form (2021-2026)

2.4 Gastrointestinal Segment by Drug Molecule

2.4.1 Small Molecule Drugs

2.4.2 Biologic Drugs

2.4.3 Gastrointestinal Market Size by Drug Molecule

2.4.3.1 Gastrointestinal Market Size CAGR by Drug Molecule (2021 VS 2025 VS 2032)

2.4.3.2 Global Gastrointestinal Market Size Market Share by Drug Molecule (2021-2026)

2.5 Gastrointestinal Segment by Application

2.5.1 Hospitals

2.5.2 Gastroenterology Clinics

2.5.3 Retail Pharmacies

2.5.4 Online Pharmacies

2.5.5 Gastrointestinal Market Size by Application

2.5.5.1 Gastrointestinal Market Size CAGR by Application (2021 VS 2025 VS 2032)

2.5.5.2 Global Gastrointestinal Market Size Market Share by Application (2021-2026)

### **3 GASTROINTESTINAL MARKET SIZE BY PLAYER**

3.1 Gastrointestinal Market Size Market Share by Player

3.1.1 Global Gastrointestinal Revenue by Player (2021-2026)

3.1.2 Global Gastrointestinal Revenue Market Share by Player (2021-2026)

3.2 Global Gastrointestinal Key Players Head office and Products Offered

3.3 Market Concentration Rate Analysis

3.3.1 Competition Landscape Analysis

3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

3.4 New Products and Potential Entrants

3.5 Mergers & Acquisitions, Expansion

### **4 GASTROINTESTINAL BY REGION**

4.1 Gastrointestinal Market Size by Region (2021-2026)

4.2 Global Gastrointestinal Annual Revenue by Country/Region (2021-2026)

4.3 Americas Gastrointestinal Market Size Growth (2021-2026)

4.4 APAC Gastrointestinal Market Size Growth (2021-2026)

4.5 Europe Gastrointestinal Market Size Growth (2021-2026)

#### 4.6 Middle East & Africa Gastrointestinal Market Size Growth (2021-2026)

### **5 AMERICAS**

#### 5.1 Americas Gastrointestinal Market Size by Country (2021-2026)

#### 5.2 Americas Gastrointestinal Market Size by Type (2021-2026)

#### 5.3 Americas Gastrointestinal Market Size by Application (2021-2026)

#### 5.4 United States

#### 5.5 Canada

#### 5.6 Mexico

#### 5.7 Brazil

### **6 APAC**

#### 6.1 APAC Gastrointestinal Market Size by Region (2021-2026)

#### 6.2 APAC Gastrointestinal Market Size by Type (2021-2026)

#### 6.3 APAC Gastrointestinal Market Size by Application (2021-2026)

#### 6.4 China

#### 6.5 Japan

#### 6.6 South Korea

#### 6.7 Southeast Asia

#### 6.8 India

#### 6.9 Australia

### **7 EUROPE**

#### 7.1 Europe Gastrointestinal Market Size by Country (2021-2026)

#### 7.2 Europe Gastrointestinal Market Size by Type (2021-2026)

#### 7.3 Europe Gastrointestinal Market Size by Application (2021-2026)

#### 7.4 Germany

#### 7.5 France

#### 7.6 UK

#### 7.7 Italy

#### 7.8 Russia

### **8 MIDDLE EAST & AFRICA**

#### 8.1 Middle East & Africa Gastrointestinal by Region (2021-2026)

#### 8.2 Middle East & Africa Gastrointestinal Market Size by Type (2021-2026)

### 8.3 Middle East & Africa Gastrointestinal Market Size by Application (2021-2026)

#### 8.4 Egypt

#### 8.5 South Africa

#### 8.6 Israel

#### 8.7 Turkey

#### 8.8 GCC Countries

## 9 MARKET DRIVERS, CHALLENGES AND TRENDS

### 9.1 Market Drivers & Growth Opportunities

### 9.2 Market Challenges & Risks

### 9.3 Industry Trends

## 10 GLOBAL GASTROINTESTINAL MARKET FORECAST

### 10.1 Global Gastrointestinal Forecast by Region (2027-2032)

#### 10.1.1 Global Gastrointestinal Forecast by Region (2027-2032)

#### 10.1.2 Americas Gastrointestinal Forecast

#### 10.1.3 APAC Gastrointestinal Forecast

#### 10.1.4 Europe Gastrointestinal Forecast

#### 10.1.5 Middle East & Africa Gastrointestinal Forecast

### 10.2 Americas Gastrointestinal Forecast by Country (2027-2032)

#### 10.2.1 United States Market Gastrointestinal Forecast

#### 10.2.2 Canada Market Gastrointestinal Forecast

#### 10.2.3 Mexico Market Gastrointestinal Forecast

#### 10.2.4 Brazil Market Gastrointestinal Forecast

### 10.3 APAC Gastrointestinal Forecast by Region (2027-2032)

#### 10.3.1 China Gastrointestinal Market Forecast

#### 10.3.2 Japan Market Gastrointestinal Forecast

#### 10.3.3 Korea Market Gastrointestinal Forecast

#### 10.3.4 Southeast Asia Market Gastrointestinal Forecast

#### 10.3.5 India Market Gastrointestinal Forecast

#### 10.3.6 Australia Market Gastrointestinal Forecast

### 10.4 Europe Gastrointestinal Forecast by Country (2027-2032)

#### 10.4.1 Germany Market Gastrointestinal Forecast

#### 10.4.2 France Market Gastrointestinal Forecast

#### 10.4.3 UK Market Gastrointestinal Forecast

#### 10.4.4 Italy Market Gastrointestinal Forecast

#### 10.4.5 Russia Market Gastrointestinal Forecast

## 10.5 Middle East & Africa Gastrointestinal Forecast by Region (2027-2032)

### 10.5.1 Egypt Market Gastrointestinal Forecast

### 10.5.2 South Africa Market Gastrointestinal Forecast

### 10.5.3 Israel Market Gastrointestinal Forecast

### 10.5.4 Turkey Market Gastrointestinal Forecast

## 10.6 Global Gastrointestinal Forecast by Type (2027-2032)

## 10.7 Global Gastrointestinal Forecast by Application (2027-2032)

### 10.7.1 GCC Countries Market Gastrointestinal Forecast

## 11 KEY PLAYERS ANALYSIS

### 11.1 AstraZeneca

#### 11.1.1 AstraZeneca Company Information

#### 11.1.2 AstraZeneca Gastrointestinal Product Offered

#### 11.1.3 AstraZeneca Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026)

#### 11.1.4 AstraZeneca Main Business Overview

#### 11.1.5 AstraZeneca Latest Developments

### 11.2 Sanofi

#### 11.2.1 Sanofi Company Information

#### 11.2.2 Sanofi Gastrointestinal Product Offered

#### 11.2.3 Sanofi Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026)

#### 11.2.4 Sanofi Main Business Overview

#### 11.2.5 Sanofi Latest Developments

### 11.3 Bayer

#### 11.3.1 Bayer Company Information

#### 11.3.2 Bayer Gastrointestinal Product Offered

#### 11.3.3 Bayer Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026)

#### 11.3.4 Bayer Main Business Overview

#### 11.3.5 Bayer Latest Developments

### 11.4 Pfizer

#### 11.4.1 Pfizer Company Information

#### 11.4.2 Pfizer Gastrointestinal Product Offered

#### 11.4.3 Pfizer Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026)

#### 11.4.4 Pfizer Main Business Overview

#### 11.4.5 Pfizer Latest Developments

### 11.5 GlaxoSmithKline

#### 11.5.1 GlaxoSmithKline Company Information

#### 11.5.2 GlaxoSmithKline Gastrointestinal Product Offered

11.5.3 GlaxoSmithKline Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026)

11.5.4 GlaxoSmithKline Main Business Overview

11.5.5 GlaxoSmithKline Latest Developments

11.6 Teva

11.6.1 Teva Company Information

11.6.2 Teva Gastrointestinal Product Offered

11.6.3 Teva Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026)

11.6.4 Teva Main Business Overview

11.6.5 Teva Latest Developments

11.7 Ferring Pharmaceuticals

11.7.1 Ferring Pharmaceuticals Company Information

11.7.2 Ferring Pharmaceuticals Gastrointestinal Product Offered

11.7.3 Ferring Pharmaceuticals Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026)

11.7.4 Ferring Pharmaceuticals Main Business Overview

11.7.5 Ferring Pharmaceuticals Latest Developments

11.8 Perrigo

11.8.1 Perrigo Company Information

11.8.2 Perrigo Gastrointestinal Product Offered

11.8.3 Perrigo Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026)

11.8.4 Perrigo Main Business Overview

11.8.5 Perrigo Latest Developments

11.9 Boehringer Ingelheim

11.9.1 Boehringer Ingelheim Company Information

11.9.2 Boehringer Ingelheim Gastrointestinal Product Offered

11.9.3 Boehringer Ingelheim Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026)

11.9.4 Boehringer Ingelheim Main Business Overview

11.9.5 Boehringer Ingelheim Latest Developments

11.10 Purdue Pharma

11.10.1 Purdue Pharma Company Information

11.10.2 Purdue Pharma Gastrointestinal Product Offered

11.10.3 Purdue Pharma Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026)

11.10.4 Purdue Pharma Main Business Overview

11.10.5 Purdue Pharma Latest Developments

11.11 Dr. Falk Pharma GmbH

11.11.1 Dr. Falk Pharma GmbH Company Information

- 11.11.2 Dr. Falk Pharma GmbH Gastrointestinal Product Offered
- 11.11.3 Dr. Falk Pharma GmbH Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026)
- 11.11.4 Dr. Falk Pharma GmbH Main Business Overview
- 11.11.5 Dr. Falk Pharma GmbH Latest Developments
- 11.12 Abbott
  - 11.12.1 Abbott Company Information
  - 11.12.2 Abbott Gastrointestinal Product Offered
  - 11.12.3 Abbott Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026)
  - 11.12.4 Abbott Main Business Overview
  - 11.12.5 Abbott Latest Developments
- 11.13 Jiangzhong
  - 11.13.1 Jiangzhong Company Information
  - 11.13.2 Jiangzhong Gastrointestinal Product Offered
  - 11.13.3 Jiangzhong Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026)
  - 11.13.4 Jiangzhong Main Business Overview
  - 11.13.5 Jiangzhong Latest Developments
- 11.14 Xian-Janssen
  - 11.14.1 Xian-Janssen Company Information
  - 11.14.2 Xian-Janssen Gastrointestinal Product Offered
  - 11.14.3 Xian-Janssen Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026)
  - 11.14.4 Xian-Janssen Main Business Overview
  - 11.14.5 Xian-Janssen Latest Developments
- 11.15 Takeda Pharmaceutical
  - 11.15.1 Takeda Pharmaceutical Company Information
  - 11.15.2 Takeda Pharmaceutical Gastrointestinal Product Offered
  - 11.15.3 Takeda Pharmaceutical Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026)
  - 11.15.4 Takeda Pharmaceutical Main Business Overview
  - 11.15.5 Takeda Pharmaceutical Latest Developments
- 11.16 AbbVie
  - 11.16.1 AbbVie Company Information
  - 11.16.2 AbbVie Gastrointestinal Product Offered
  - 11.16.3 AbbVie Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026)
  - 11.16.4 AbbVie Main Business Overview

- 11.16.5 AbbVie Latest Developments
- 11.17 Eli Lilly and Company
  - 11.17.1 Eli Lilly and Company Company Information
  - 11.17.2 Eli Lilly and Company Gastrointestinal Product Offered
  - 11.17.3 Eli Lilly and Company Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026)
  - 11.17.4 Eli Lilly and Company Main Business Overview
  - 11.17.5 Eli Lilly and Company Latest Developments
- 11.18 Johnson & Johnson
  - 11.18.1 Johnson & Johnson Company Information
  - 11.18.2 Johnson & Johnson Gastrointestinal Product Offered
  - 11.18.3 Johnson & Johnson Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026)
  - 11.18.4 Johnson & Johnson Main Business Overview
  - 11.18.5 Johnson & Johnson Latest Developments
- 11.19 Bristol Myers Squibb
  - 11.19.1 Bristol Myers Squibb Company Information
  - 11.19.2 Bristol Myers Squibb Gastrointestinal Product Offered
  - 11.19.3 Bristol Myers Squibb Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026)
  - 11.19.4 Bristol Myers Squibb Main Business Overview
  - 11.19.5 Bristol Myers Squibb Latest Developments
- 11.20 Bausch Health
  - 11.20.1 Bausch Health Company Information
  - 11.20.2 Bausch Health Gastrointestinal Product Offered
  - 11.20.3 Bausch Health Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026)
  - 11.20.4 Bausch Health Main Business Overview
  - 11.20.5 Bausch Health Latest Developments
- 11.21 Livzon Pharmaceutical
  - 11.21.1 Livzon Pharmaceutical Company Information
  - 11.21.2 Livzon Pharmaceutical Gastrointestinal Product Offered
  - 11.21.3 Livzon Pharmaceutical Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026)
  - 11.21.4 Livzon Pharmaceutical Main Business Overview
  - 11.21.5 Livzon Pharmaceutical Latest Developments
- 11.22 Shandong Luoxin Pharmaceutical
  - 11.22.1 Shandong Luoxin Pharmaceutical Company Information
  - 11.22.2 Shandong Luoxin Pharmaceutical Gastrointestinal Product Offered

11.22.3 Shandong Luoxin Pharmaceutical Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026)

11.22.4 Shandong Luoxin Pharmaceutical Main Business Overview

11.22.5 Shandong Luoxin Pharmaceutical Latest Developments

11.23 Gilead Sciences

11.23.1 Gilead Sciences Company Information

11.23.2 Gilead Sciences Gastrointestinal Product Offered

11.23.3 Gilead Sciences Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026)

11.23.4 Gilead Sciences Main Business Overview

11.23.5 Gilead Sciences Latest Developments

11.24 Zhengdatianqing

11.24.1 Zhengdatianqing Company Information

11.24.2 Zhengdatianqing Gastrointestinal Product Offered

11.24.3 Zhengdatianqing Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026)

11.24.4 Zhengdatianqing Main Business Overview

11.24.5 Zhengdatianqing Latest Developments

11.25 Zydus Lifesciences

11.25.1 Zydus Lifesciences Company Information

11.25.2 Zydus Lifesciences Gastrointestinal Product Offered

11.25.3 Zydus Lifesciences Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026)

11.25.4 Zydus Lifesciences Main Business Overview

11.25.5 Zydus Lifesciences Latest Developments

## **12 RESEARCH FINDINGS AND CONCLUSION**

## List Of Tables

### LIST OF TABLES

Table 1. Gastrointestinal Market Size CAGR by Region (2021 VS 2025 VS 2032) & (\$ millions)

Table 2. Gastrointestinal Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)

Table 3. Major Players of Acid-Related Disorder Drugs

Table 4. Major Players of Inflammatory Bowel Disease Drugs

Table 5. Major Players of Irritable Bowel Syndrome Drugs

Table 6. Major Players of Constipation Drugs

Table 7. Major Players of Diarrhea Drugs

Table 8. Major Players of Gastrointestinal Motility Disorder Drugs

Table 9. Major Players of Other Gastrointestinal Drugs

Table 10. Gastrointestinal Market Size CAGR by Type (2021 VS 2025 VS 2032) & (\$ millions)

Table 11. Global Gastrointestinal Market Size by Type (2021-2026) & (\$ millions)

Table 12. Global Gastrointestinal Market Size Market Share by Type (2021-2026)

Table 13. Major Players of Oral Solid Preparations

Table 14. Major Players of Oral Liquid and Suspension Preparations

Table 15. Major Players of Injectable Preparations

Table 16. Major Players of Rectal Preparations

Table 17. Major Players of Other Preparations

Table 18. Gastrointestinal Market Size CAGR by Primary Dosage Form (2021 VS 2025 VS 2032) & (\$ millions)

Table 19. Global Gastrointestinal Market Size by Primary Dosage Form (2021-2026) & (\$ millions)

Table 20. Global Gastrointestinal Market Size Market Share by Primary Dosage Form (2021-2026)

Table 21. Major Players of Small Molecule Drugs

Table 22. Major Players of Biologic Drugs

Table 23. Gastrointestinal Market Size CAGR by Drug Molecule (2021 VS 2025 VS 2032) & (\$ millions)

Table 24. Global Gastrointestinal Market Size by Drug Molecule (2021-2026) & (\$ millions)

Table 25. Global Gastrointestinal Market Size Market Share by Drug Molecule (2021-2026)

Table 26. Gastrointestinal Market Size CAGR by Application (2021 VS 2025 VS 2032) &

(\$ millions)

Table 27. Global Gastrointestinal Market Size by Application (2021-2026) & (\$ millions)

Table 28. Global Gastrointestinal Market Size Market Share by Application (2021-2026)

Table 29. Global Gastrointestinal Revenue by Player (2021-2026) & (\$ millions)

Table 30. Global Gastrointestinal Revenue Market Share by Player (2021-2026)

Table 31. Gastrointestinal Key Players Head office and Products Offered

Table 32. Gastrointestinal Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

Table 33. New Products and Potential Entrants

Table 34. Mergers & Acquisitions, Expansion

Table 35. Global Gastrointestinal Market Size by Region (2021-2026) & (\$ millions)

Table 36. Global Gastrointestinal Market Size Market Share by Region (2021-2026)

Table 37. Global Gastrointestinal Revenue by Country/Region (2021-2026) & (\$ millions)

Table 38. Global Gastrointestinal Revenue Market Share by Country/Region (2021-2026)

Table 39. Americas Gastrointestinal Market Size by Country (2021-2026) & (\$ millions)

Table 40. Americas Gastrointestinal Market Size Market Share by Country (2021-2026)

Table 41. Americas Gastrointestinal Market Size by Type (2021-2026) & (\$ millions)

Table 42. Americas Gastrointestinal Market Size Market Share by Type (2021-2026)

Table 43. Americas Gastrointestinal Market Size by Application (2021-2026) & (\$ millions)

Table 44. Americas Gastrointestinal Market Size Market Share by Application (2021-2026)

Table 45. APAC Gastrointestinal Market Size by Region (2021-2026) & (\$ millions)

Table 46. APAC Gastrointestinal Market Size Market Share by Region (2021-2026)

Table 47. APAC Gastrointestinal Market Size by Type (2021-2026) & (\$ millions)

Table 48. APAC Gastrointestinal Market Size by Application (2021-2026) & (\$ millions)

Table 49. Europe Gastrointestinal Market Size by Country (2021-2026) & (\$ millions)

Table 50. Europe Gastrointestinal Market Size Market Share by Country (2021-2026)

Table 51. Europe Gastrointestinal Market Size by Type (2021-2026) & (\$ millions)

Table 52. Europe Gastrointestinal Market Size by Application (2021-2026) & (\$ millions)

Table 53. Middle East & Africa Gastrointestinal Market Size by Region (2021-2026) & (\$ millions)

Table 54. Middle East & Africa Gastrointestinal Market Size by Type (2021-2026) & (\$ millions)

Table 55. Middle East & Africa Gastrointestinal Market Size by Application (2021-2026) & (\$ millions)

Table 56. Key Market Drivers & Growth Opportunities of Gastrointestinal

Table 57. Key Market Challenges & Risks of Gastrointestinal

Table 58. Key Industry Trends of Gastrointestinal

Table 59. Global Gastrointestinal Market Size Forecast by Region (2027-2032) & (\$ millions)

Table 60. Global Gastrointestinal Market Size Market Share Forecast by Region (2027-2032)

Table 61. Global Gastrointestinal Market Size Forecast by Type (2027-2032) & (\$ millions)

Table 62. Global Gastrointestinal Market Size Forecast by Application (2027-2032) & (\$ millions)

Table 63. AstraZeneca Details, Company Type, Gastrointestinal Area Served and Its Competitors

Table 64. AstraZeneca Gastrointestinal Product Offered

Table 65. AstraZeneca Gastrointestinal Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 66. AstraZeneca Main Business

Table 67. AstraZeneca Latest Developments

Table 68. Sanofi Details, Company Type, Gastrointestinal Area Served and Its Competitors

Table 69. Sanofi Gastrointestinal Product Offered

Table 70. Sanofi Gastrointestinal Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 71. Sanofi Main Business

Table 72. Sanofi Latest Developments

Table 73. Bayer Details, Company Type, Gastrointestinal Area Served and Its Competitors

Table 74. Bayer Gastrointestinal Product Offered

Table 75. Bayer Gastrointestinal Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 76. Bayer Main Business

Table 77. Bayer Latest Developments

Table 78. Pfizer Details, Company Type, Gastrointestinal Area Served and Its Competitors

Table 79. Pfizer Gastrointestinal Product Offered

Table 80. Pfizer Gastrointestinal Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 81. Pfizer Main Business

Table 82. Pfizer Latest Developments

Table 83. GlaxoSmithKline Details, Company Type, Gastrointestinal Area Served and Its Competitors

Table 84. GlaxoSmithKline Gastrointestinal Product Offered

Table 85. GlaxoSmithKline Gastrointestinal Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 86. GlaxoSmithKline Main Business

Table 87. GlaxoSmithKline Latest Developments

Table 88. Teva Details, Company Type, Gastrointestinal Area Served and Its Competitors

Table 89. Teva Gastrointestinal Product Offered

Table 90. Teva Gastrointestinal Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 91. Teva Main Business

Table 92. Teva Latest Developments

Table 93. Ferring Pharmaceuticals Details, Company Type, Gastrointestinal Area Served and Its Competitors

Table 94. Ferring Pharmaceuticals Gastrointestinal Product Offered

Table 95. Ferring Pharmaceuticals Gastrointestinal Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 96. Ferring Pharmaceuticals Main Business

Table 97. Ferring Pharmaceuticals Latest Developments

Table 98. Perrigo Details, Company Type, Gastrointestinal Area Served and Its Competitors

Table 99. Perrigo Gastrointestinal Product Offered

Table 100. Perrigo Gastrointestinal Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 101. Perrigo Main Business

Table 102. Perrigo Latest Developments

Table 103. Boehringer Ingelheim Details, Company Type, Gastrointestinal Area Served and Its Competitors

Table 104. Boehringer Ingelheim Gastrointestinal Product Offered

Table 105. Boehringer Ingelheim Gastrointestinal Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 106. Boehringer Ingelheim Main Business

Table 107. Boehringer Ingelheim Latest Developments

Table 108. Purdue Pharma Details, Company Type, Gastrointestinal Area Served and Its Competitors

Table 109. Purdue Pharma Gastrointestinal Product Offered

Table 110. Purdue Pharma Gastrointestinal Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 111. Purdue Pharma Main Business

Table 112. Purdue Pharma Latest Developments

Table 113. Dr. Falk Pharma GmbH Details, Company Type, Gastrointestinal Area Served and Its Competitors

Table 114. Dr. Falk Pharma GmbH Gastrointestinal Product Offered

Table 115. Dr. Falk Pharma GmbH Gastrointestinal Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 116. Dr. Falk Pharma GmbH Main Business

Table 117. Dr. Falk Pharma GmbH Latest Developments

Table 118. Abbott Details, Company Type, Gastrointestinal Area Served and Its Competitors

Table 119. Abbott Gastrointestinal Product Offered

Table 120. Abbott Gastrointestinal Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 121. Abbott Main Business

Table 122. Abbott Latest Developments

Table 123. Jiangzhong Details, Company Type, Gastrointestinal Area Served and Its Competitors

Table 124. Jiangzhong Gastrointestinal Product Offered

Table 125. Jiangzhong Gastrointestinal Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 126. Jiangzhong Main Business

Table 127. Jiangzhong Latest Developments

Table 128. Xian-Janssen Details, Company Type, Gastrointestinal Area Served and Its Competitors

Table 129. Xian-Janssen Gastrointestinal Product Offered

Table 130. Xian-Janssen Gastrointestinal Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 131. Xian-Janssen Main Business

Table 132. Xian-Janssen Latest Developments

Table 133. Takeda Pharmaceutical Details, Company Type, Gastrointestinal Area Served and Its Competitors

Table 134. Takeda Pharmaceutical Gastrointestinal Product Offered

Table 135. Takeda Pharmaceutical Gastrointestinal Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 136. Takeda Pharmaceutical Main Business

Table 137. Takeda Pharmaceutical Latest Developments

Table 138. AbbVie Details, Company Type, Gastrointestinal Area Served and Its Competitors

Table 139. AbbVie Gastrointestinal Product Offered

Table 140. AbbVie Gastrointestinal Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 141. AbbVie Main Business

Table 142. AbbVie Latest Developments

Table 143. Eli Lilly and Company Details, Company Type, Gastrointestinal Area Served and Its Competitors

Table 144. Eli Lilly and Company Gastrointestinal Product Offered

Table 145. Eli Lilly and Company Gastrointestinal Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 146. Eli Lilly and Company Main Business

Table 147. Eli Lilly and Company Latest Developments

Table 148. Johnson & Johnson Details, Company Type, Gastrointestinal Area Served and Its Competitors

Table 149. Johnson & Johnson Gastrointestinal Product Offered

Table 150. Johnson & Johnson Gastrointestinal Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 151. Johnson & Johnson Main Business

Table 152. Johnson & Johnson Latest Developments

Table 153. Bristol Myers Squibb Details, Company Type, Gastrointestinal Area Served and Its Competitors

Table 154. Bristol Myers Squibb Gastrointestinal Product Offered

Table 155. Bristol Myers Squibb Gastrointestinal Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 156. Bristol Myers Squibb Main Business

Table 157. Bristol Myers Squibb Latest Developments

Table 158. Bausch Health Details, Company Type, Gastrointestinal Area Served and Its Competitors

Table 159. Bausch Health Gastrointestinal Product Offered

Table 160. Bausch Health Gastrointestinal Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 161. Bausch Health Main Business

Table 162. Bausch Health Latest Developments

Table 163. Livzon Pharmaceutical Details, Company Type, Gastrointestinal Area Served and Its Competitors

Table 164. Livzon Pharmaceutical Gastrointestinal Product Offered

Table 165. Livzon Pharmaceutical Gastrointestinal Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 166. Livzon Pharmaceutical Main Business

Table 167. Livzon Pharmaceutical Latest Developments

Table 168. Shandong Luoxin Pharmaceutical Details, Company Type, Gastrointestinal Area Served and Its Competitors

Table 169. Shandong Luoxin Pharmaceutical Gastrointestinal Product Offered

Table 170. Shandong Luoxin Pharmaceutical Gastrointestinal Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 171. Shandong Luoxin Pharmaceutical Main Business

Table 172. Shandong Luoxin Pharmaceutical Latest Developments

Table 173. Gilead Sciences Details, Company Type, Gastrointestinal Area Served and Its Competitors

Table 174. Gilead Sciences Gastrointestinal Product Offered

Table 175. Gilead Sciences Gastrointestinal Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 176. Gilead Sciences Main Business

Table 177. Gilead Sciences Latest Developments

Table 178. Zhengdatianqing Details, Company Type, Gastrointestinal Area Served and Its Competitors

Table 179. Zhengdatianqing Gastrointestinal Product Offered

Table 180. Zhengdatianqing Gastrointestinal Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 181. Zhengdatianqing Main Business

Table 182. Zhengdatianqing Latest Developments

Table 183. Zydus Lifesciences Details, Company Type, Gastrointestinal Area Served and Its Competitors

Table 184. Zydus Lifesciences Gastrointestinal Product Offered

Table 185. Zydus Lifesciences Gastrointestinal Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 186. Zydus Lifesciences Main Business

Table 187. Zydus Lifesciences Latest Developments

## List Of Figures

### LIST OF FIGURES

- Figure 1. Gastrointestinal Report Years Considered
- Figure 2. Research Objectives
- Figure 3. Research Methodology
- Figure 4. Research Process and Data Source
- Figure 5. Global Gastrointestinal Market Size Growth Rate (2021-2032) (\$ millions)
- Figure 6. Gastrointestinal Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)
- Figure 7. Gastrointestinal Sales Market Share by Country/Region (2025)
- Figure 8. Gastrointestinal Sales Market Share by Country/Region (2021, 2025 & 2032)
- Figure 9. Global Gastrointestinal Market Size Market Share by Type in 2025
- Figure 10. Global Gastrointestinal Market Size Market Share by Primary Dosage Form in 2025
- Figure 11. Global Gastrointestinal Market Size Market Share by Drug Molecule in 2025
- Figure 12. Gastrointestinal in Hospitals
- Figure 13. Global Gastrointestinal Market: Hospitals (2021-2026) & (\$ millions)
- Figure 14. Gastrointestinal in Gastroenterology Clinics
- Figure 15. Global Gastrointestinal Market: Gastroenterology Clinics (2021-2026) & (\$ millions)
- Figure 16. Gastrointestinal in Retail Pharmacies
- Figure 17. Global Gastrointestinal Market: Retail Pharmacies (2021-2026) & (\$ millions)
- Figure 18. Gastrointestinal in Online Pharmacies
- Figure 19. Global Gastrointestinal Market: Online Pharmacies (2021-2026) & (\$ millions)
- Figure 20. Global Gastrointestinal Market Size Market Share by Application in 2025
- Figure 21. Global Gastrointestinal Revenue Market Share by Player in 2025
- Figure 22. Global Gastrointestinal Market Size Market Share by Region (2021-2026)
- Figure 23. Americas Gastrointestinal Market Size 2021-2026 (\$ millions)
- Figure 24. APAC Gastrointestinal Market Size 2021-2026 (\$ millions)
- Figure 25. Europe Gastrointestinal Market Size 2021-2026 (\$ millions)
- Figure 26. Middle East & Africa Gastrointestinal Market Size 2021-2026 (\$ millions)
- Figure 27. Americas Gastrointestinal Value Market Share by Country in 2025
- Figure 28. United States Gastrointestinal Market Size Growth 2021-2026 (\$ millions)
- Figure 29. Canada Gastrointestinal Market Size Growth 2021-2026 (\$ millions)
- Figure 30. Mexico Gastrointestinal Market Size Growth 2021-2026 (\$ millions)
- Figure 31. Brazil Gastrointestinal Market Size Growth 2021-2026 (\$ millions)

- Figure 32. APAC Gastrointestinal Market Size Market Share by Region in 2025
- Figure 33. APAC Gastrointestinal Market Size Market Share by Type (2021-2026)
- Figure 34. APAC Gastrointestinal Market Size Market Share by Application (2021-2026)
- Figure 35. China Gastrointestinal Market Size Growth 2021-2026 (\$ millions)
- Figure 36. Japan Gastrointestinal Market Size Growth 2021-2026 (\$ millions)
- Figure 37. South Korea Gastrointestinal Market Size Growth 2021-2026 (\$ millions)
- Figure 38. Southeast Asia Gastrointestinal Market Size Growth 2021-2026 (\$ millions)
- Figure 39. India Gastrointestinal Market Size Growth 2021-2026 (\$ millions)
- Figure 40. Australia Gastrointestinal Market Size Growth 2021-2026 (\$ millions)
- Figure 41. Europe Gastrointestinal Market Size Market Share by Country in 2025
- Figure 42. Europe Gastrointestinal Market Size Market Share by Type (2021-2026)
- Figure 43. Europe Gastrointestinal Market Size Market Share by Application (2021-2026)
- Figure 44. Germany Gastrointestinal Market Size Growth 2021-2026 (\$ millions)
- Figure 45. France Gastrointestinal Market Size Growth 2021-2026 (\$ millions)
- Figure 46. UK Gastrointestinal Market Size Growth 2021-2026 (\$ millions)
- Figure 47. Italy Gastrointestinal Market Size Growth 2021-2026 (\$ millions)
- Figure 48. Russia Gastrointestinal Market Size Growth 2021-2026 (\$ millions)
- Figure 49. Middle East & Africa Gastrointestinal Market Size Market Share by Region (2021-2026)
- Figure 50. Middle East & Africa Gastrointestinal Market Size Market Share by Type (2021-2026)
- Figure 51. Middle East & Africa Gastrointestinal Market Size Market Share by Application (2021-2026)
- Figure 52. Egypt Gastrointestinal Market Size Growth 2021-2026 (\$ millions)
- Figure 53. South Africa Gastrointestinal Market Size Growth 2021-2026 (\$ millions)
- Figure 54. Israel Gastrointestinal Market Size Growth 2021-2026 (\$ millions)
- Figure 55. Turkey Gastrointestinal Market Size Growth 2021-2026 (\$ millions)
- Figure 56. GCC Countries Gastrointestinal Market Size Growth 2021-2026 (\$ millions)
- Figure 57. Americas Gastrointestinal Market Size 2027-2032 (\$ millions)
- Figure 58. APAC Gastrointestinal Market Size 2027-2032 (\$ millions)
- Figure 59. Europe Gastrointestinal Market Size 2027-2032 (\$ millions)
- Figure 60. Middle East & Africa Gastrointestinal Market Size 2027-2032 (\$ millions)
- Figure 61. United States Gastrointestinal Market Size 2027-2032 (\$ millions)
- Figure 62. Canada Gastrointestinal Market Size 2027-2032 (\$ millions)
- Figure 63. Mexico Gastrointestinal Market Size 2027-2032 (\$ millions)
- Figure 64. Brazil Gastrointestinal Market Size 2027-2032 (\$ millions)
- Figure 65. China Gastrointestinal Market Size 2027-2032 (\$ millions)
- Figure 66. Japan Gastrointestinal Market Size 2027-2032 (\$ millions)

- Figure 67. Korea Gastrointestinal Market Size 2027-2032 (\$ millions)
- Figure 68. Southeast Asia Gastrointestinal Market Size 2027-2032 (\$ millions)
- Figure 69. India Gastrointestinal Market Size 2027-2032 (\$ millions)
- Figure 70. Australia Gastrointestinal Market Size 2027-2032 (\$ millions)
- Figure 71. Germany Gastrointestinal Market Size 2027-2032 (\$ millions)
- Figure 72. France Gastrointestinal Market Size 2027-2032 (\$ millions)
- Figure 73. UK Gastrointestinal Market Size 2027-2032 (\$ millions)
- Figure 74. Italy Gastrointestinal Market Size 2027-2032 (\$ millions)
- Figure 75. Russia Gastrointestinal Market Size 2027-2032 (\$ millions)
- Figure 76. Egypt Gastrointestinal Market Size 2027-2032 (\$ millions)
- Figure 77. South Africa Gastrointestinal Market Size 2027-2032 (\$ millions)
- Figure 78. Israel Gastrointestinal Market Size 2027-2032 (\$ millions)
- Figure 79. Turkey Gastrointestinal Market Size 2027-2032 (\$ millions)
- Figure 80. Global Gastrointestinal Market Size Market Share Forecast by Type (2027-2032)
- Figure 81. Global Gastrointestinal Market Size Market Share Forecast by Application (2027-2032)
- Figure 82. GCC Countries Gastrointestinal Market Size 2027-2032 (\$ millions)

## I would like to order

Product name: Global Gastrointestinal Market Growth (Status and Outlook) 2026-2032

Product link: <https://marketpublishers.com/r/G5D2AAEDFA67EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G5D2AAEDFA67EN.html>